Published online: 2024 September 3.

Research Article



Changing Epidemiology of Chronic Hepatitis C: A University Hospital Experience

Süheyla Kömür 🝺 ^{1,*}, Behice Kurtaran ¹, Yusuf Kemal Arslan ², Ferit Kuscu ¹, Sezin Hoşgel Sevdimbaş ¹, Seza Ayse Inal ¹, Aslıhan Candevir ¹, Yesim Tasova ¹

¹ Department of Infectious Disease, Cukurova University Faculty of Medicine, Adana, Turkey ² Department of Biostatistics, Cukurova University Faculty of Medicine, Adana, Turkey

Corresponding author: Department of Infectious Disease, Cukurova University Faculty of Medicine, Adana, Turkey. Email: skomur@gmail.com

Received 2024 April 27; Revised 2024 July 7; Accepted 2024 August 2.

Abstract

Background: Hepatitis C virus (HCV) infection remains a significant public health problem worldwide, with varying epidemiological trends over time necessitating continual surveillance and intervention strategies.

Objectives: This retrospective study aimed to examine trends in demographics, transmission routes, and disease characteristics among 635 patients diagnosed with HCV infection between 2003 and 2023.

Methods: Data on demographics, HCV RNA levels, liver enzymes, genotype distribution, and transmission routes were retrospectively analyzed. The study period was divided into four segments for detailed analysis.

Results: There was a gradual increase in the diagnosed cases over the study period, particularly noticeable after 2012. The mean age at diagnosis remained stable from 2003 - 2007 to 2008 - 2012 but decreased significantly in the following years (P = 0.001). Male predominance was observed throughout the study, with a notable increase in the male/female ratio over time (P < 0.001). Intravenous drug use (IVDU) emerged as the predominant transmission route, reaching 68.3% in 2018 - 2022 (P < 0.001). The prevalence of incarceration history among patients increased significantly, reaching 24.6% in 2018 - 2022 (P < 0.001). Disease characteristics varied between periods; median HCV RNA levels were highest in 2018 - 2022, and median alanine aminotransferase (ALT) levels differed significantly between periods (P = 0.001). The genotype distribution showed a shift over time, with genotype 1 predominating initially and genotypes 3, 4, and 5 becoming more prevalent in later years (P < 0.001). **Conclusions:** This study highlights the dynamic changes in hepatitis C epidemiology over two decades in southern Turkey, highlighting the increasing burden in younger populations, the increasing prevalence of IVDU as a transmission route, and the changing genotype distribution.

Keywords: Hepatitis C, Epidemiology, Intravenous Drug Users, Modes of Transmission

1. Background

Hepatitis C virus (HCV) infection is an ongoing health problem affecting a large number of individuals worldwide (1). It is estimated to affect 1% of the population in most countries globally, with about 71 million chronic infections and about 400.000 deaths annually (2). The Eastern Mediterranean and European regions have the highest burden of disease (3).

In Turkey, the seroprevalence of HCV was 0.5% and 1% (4). This means that around 250,000 - 550,000 people over the age of 18 are estimated to be infected with HCV, with the majority of the infected individuals unaware of

their condition. Despite its low endemicity, HCV is the second leading cause of liver transplantation in Turkey. If left untreated, HCV is expected to increase the disease burden and mortality steadily over the next 20 years (5-7). To develop effective management and prevention strategies, it is crucial to understand the epidemiological trends, clinical characteristics, and factors influencing disease transmission. Based on the purpose of these factors, this study has examined the demographic, clinical, and virological profiles of patients diagnosed with hepatitis C from 2003 to 2023 over two decades in a central hospital in the southern region of Turkey.

Copyright © 2024, Kömür et al. This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.

2. Objectives

It aimed to highlight the importance of continuous surveillance, targeted prevention efforts, and individualised management strategies to reduce the burden of hepatitis C and improve patient outcomes.

3. Methods

This study reviewed adults admitted to Balcalı Hospital, Department of Infectious Diseases, who tested positive for anti-HCV and HCV RNA. Balcalı Hospital is located in Adana, Turkey, and is affiliated with Çukurova University, a prominent educational and research institution in southern Turkey. The demographic characteristics, admission dates, hepatitis B virus (HBV) coinfection status, HCV genotypes, HCV RNA values, and liver enzymes were recorded.

3.1. Inclusion Criteria

1. Patients aged 18 and older;

2. Patients diagnosed with HCV from January 2003 to January 2023;

3. Anti-HCV positive patients whose initial HCV RNA levels were measured.

3.2. Exclusion Criteria

1. Patients under the age of 18;

2. Patients with undetectable initial HCV RNA for any reason.

An anti-HCV antibody test was performed using a chemiluminescent microparticle enzyme immunoassay (CMIA) (Architect, Anti-HCV, Abbott, USA) following manufacturer's guidelines.

Hepatitis C virus RNA quantitation in serum was performed using a real-time polymerase chain reaction (PCR) test kit (COBAS AmpliPrep/COBAS TaqMan HCV real-time PCR, Roche diagnostics, Germany). For HCV genotype determination, the HCV Genotype Plus real-TM (Sacace Biotechnologies, Italy) kit was used.

3.3. Statistical Analysis

The data in the study were presented according to the following conventions: Categorical data were presented as number (n) and percentage (%), while numerical data were displayed as mean \pm standard deviation or median (Q1 - Q3). The Fisher's exact test was used to compare categorical measurements between groups. In addition, the Kolmogorov-Smirnov test was applied to assess whether the numerical measurements met the assumption of normal distribution. Moreover, the Kruskal-Walli's test was utilized for a general comparison of numerical measurements that did not demonstrate a normal distribution among more than two groups. In cases where the general comparison was significant, Dunn's test was conducted for pairwise group comparisons, and lettering was assigned according to the corrected p-values. The statistical analysis of the data was performed using the IBM SPSS 20.0 package. All tests were conducted with a statistical significance level of 0.05.

4. Results

A total of 635 patients were studied from 2003 to 2023. The patient distribution was analyzed over four periods, and the number of patients increased gradually over time (Figure 1).

The mean age at diagnosis was 42.3 ± 17.4 years (range = 12-89), and no statistically significant difference was found between 2003 - 2007 and 2008-2012 (P = 0.776). These years exhibited a higher age at diagnosis compared to 2013 - 2017 and 2018 - 2022 periods, indicating a decreasing trend in the age at diagnosis over the years (Figure 2).

Out of the patients, 71% were male. The gender distribution of patients diagnosed with HCV was analysed by year. It was concluded that the proportion of male patients increased over the years, while the proportion of female patients gradually decreased (Figure 2). Gender ratios were found to be statistically different across years (P < 0.001).

In 55.4% of the patients, the transmission route was unknown. It was found that the cause of transmission was unknown at a high rate in 2012 and the previous period, while the rate of unknown transmission was lower in the following years. The most common transmission route was intravenous drug use (IVDU), accounting for 40.3%. The rate of IVDU was 46.3% between 2013 and 2017 and 68.3% between 2018 and 2022 (Table 1).

The proportion of patients with a prison history was 9.1%. Upon analyzing the prison history, it was observed that none of the patients had a prison history in 2003 - 2007 and 2008 - 2012. In 2013 - 2017, 5.2% of the patients had a prison history, while in 2018 - 2022, 24.6% had a prison history. The rate was significantly higher between 2018 and 2022 than in the other year intervals (P < 0.001).

The mean values of HCV RNA, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) levels are shown in Table 2. The median value of



Figure 1. A, the number; and B, proportion of patients by age and sex over the years



HCV RNA was higher in the 2018 - 2022 year interval than in the other years. Aspartate aminotransferase levels were similar across the groups (P = 0.148), while ALT levels showed a significant difference (P = 0.001) (Table 2). The distribution of genotypes was found to be statistically different across time periods (P < 0.001). Genotype 1 was the most prevalent between 2003 and 2007, with no instances of genotype 5 observed. This trend continued in 2008 - 2012. However, the rates of genotype 3, genotype 4, and genotype 5 were higher in

Table 1. Hepatitis C Transmission Routes in Different Time Pe	eriods ^{a, b}
---	------------------------

Transmission Boutos	Time Period					
Italishiission Routes	2003-2007	2008 - 2012	2013 - 2017	2018 - 2022	r-value	
Unknown	91 (98.9)	98 (97.0)	102 (46.8)	61 (27.2)		
IVDU	0 (0.0)	2 (2.0)	101 (46.3)	153 (68.3)	<0.001	
Hemodialysis	0 (0.0)	0(0.0)	9 (4.1)	5 (2.2)	<0.001	
Unsafe procedure	1 (1.1)	1 (1.1)	6 (2.7)	5 (2.2)		
Total (n)	92	101	218	224	-	

Abbreviation: IVDU, intravenous drug use.

^a Unsafe procedure: Unsafe tattooing or piercing, or receiving medical care with improperly sterilized or reused medical equipment, particularly in settings with inadequate infection control practices.

^b Values are expressed as No. (%).

Table 2. Temporal Trends in Hepatitis C Virus RNA, Aspartate Aminotransferase, and Alanine Aminotransferase Levels in Different Time Periods ^{a, b}							
Variables			Time Period			D Value	
variables	2002 2022	2002 2005	2000 2012	2012 2015	2010 2022	- r-value	

	2003-2023	2003-2007	2008-2012	2013 - 2017	2018 - 2022	
HCV RNA; (IU/mL)	970000	906500 ^A (179193 - 2370000)	543000 ^A (80000 - 2400000)	845041 ^A (213000 - 3360000)	1851000 ^B (265000 - 7457000)	< 0.001
AST; (IU/L)	35	35 (25 - 58)	36 (28 - 57)	36 (28 - 51)	34 (25 - 46)	0.148
ALT; (IU/L)	40	33 (24 - 54) ^A	34 (27 - 50) ^A	43 (33 - 70) ^B	43 (27 - 66) ^{AB}	0.001

Abbreviations: HCV, hepatitis C virus; AST, aspartate aminotransferase; ALT, alanine aminotransferase.

^a For the variable of interest, the same capital letters indicate that the groups are similar, whereas different capital letters indicate a statistically significant difference.

^b Results are presented as median (Q1 - Q3).

the last two time periods than in the previous years (Figure 3).

5. Discussion

The findings of this study offer insightful information about the changing landscape of hepatitis C diagnosis, demographics, transmission routes, and disease characteristics from 2003 to 2023. Understanding these trends is crucial for informing public health strategies and clinical management approaches. In this discussion, we will delve into the implications of the key findings and their broader significance.

A notable trend observed in this study is the gradual increase in the number of diagnosed hepatitis C cases over the four periods analyzed. The number of patients increased gradually over time, particularly after 2012. This rise could be attributed to several factors, including increased awareness, improved screening programs, and changes in risk behaviors within the population. In a study published in 2012, it was reported that the prevalence of anti-HCV was between 0.5% and 1% in our country (8). Accordingly, it is estimated that approximately 250,000 - 550,000 adults are infected

with HCV, and the majority of them are unaware of their condition. A study published in 2014 estimated that 514,000 people (0.7% of the population) were infected with HCV in Turkey as of 2013. According to the same study, it was estimated that 81,300 (16%) people were infected with HCV, with 5,500 (1.1%) newly diagnosed cases and 4,200 (0.8%) patients receiving annual treatment. While the number of individuals with hepatocellular carcinoma (HCC) was 2,230 in 2013, it is estimated to increase by 70% in 2030. Similarly, liverrelated deaths are expected to increase by 70% above the 2013 level in 2020 and by 60% and 40% in decompensated and compensated cirrhosis. respectively (6, 9-11). In our study, it was suggested that the increase in the number of cases might be due to the widespread use of screening programs, increased awareness, and the rise in the number of diagnosed patients (6). In the United States, the incidence of new hepatitis C infections reported to the Centers for Disease Control and Prevention (CDC) in 2018 was four times higher than that in 2009. In addition, 2018 marked a decade of increasing incidence of new hepatitis C infections in those aged between 20 and 30, with IVDU representing the predominant transmission route (12). Consequently, the CDC updated screening



Figure 3. Hepatitis C virus (HCV) genotypic distribution by the years

recommendations and offered universal HCV screening among adults and pregnant women. The findings underscore the importance of ongoing surveillance and intervention efforts to effectively address the growing burden of hepatitis C (13).

While the mean age at diagnosis remained relatively stable between 2003 - 2007 and 2008 - 2012, a notable decline was noted in subsequent years. This shift may reflect changing patterns of transmission and evolving risk profiles among different age groups. The gender distribution of hepatitis C patients also showed notable changes over time, with a higher proportion of male patients observed across all periods. This finding aligns with existing literature, suggesting a higher prevalence of HCV among males, possibly due to differential exposure to risk factors, such as IVDU and occupational hazards. The increasing proportion of male patients over the years underscores the need for targeted interventions tailored to address gender-specific risk factors and access barriers to testing and treatment. According to the 2020 European CDC Annual Epidemiological Report, hepatitis C was more commonly reported among men than women, with a male-to-female ratio of 2.2:1. The most affected age group among males was 35 - 44 years, while among females, it was 25 - 44 years (10). In our study, the mean age was 42.3, and the male-to-female ratio was 2.4:1. In a study in Turkey, the mean age was reported to be 52, and 52.4% of the study population was female. This study was conducted in Istanbul, and different results may be due to sociocultural differences with our region (11). In a study cohort conducted in Italy, 51.0% of patients were female, with a mean age of 47.5 years for female patients and 50.5 years for male patients (14). In our study, it was concluded that the proportion of male patients increased over the years, and the proportion of female patients gradually decreased (Figure 2). Gender ratios were found to be statistically different according to years (P < 0.001).

In 55.4% of the patients, the transmission route was unknown, and the cause of transmission was unknown at a high rate in 2012 and the previous period, while this rate was lower in the following years. The most frequently reported transmission route was IVDU, accounting for 40.3% of cases. The rate of IVDU was 46.3% between 2013 and 2017 and 68.3% between 2018 and 2022 (Table 1). In the ECDC Annual Epidemiological Report. the transmission route was reported for just 31% of cases, and similar to our study, the most commonly reported transmission route was IVDU, accounting for 59% of cases with complete information on transmission status (10). Initially, IVDU emerged as a significant transmission route in industrialized countries during the 1960s. However, it has since spread to affect numerous countries worldwide, including both urban and rural areas. In the United States, for instance, IVDU has recently emerged as a prominent issue, particularly in certain regions. In our country, the prevalence of HCV in patients receiving treatment in addiction treatment centers is around 50% (15). In countries like ours, where harm reduction policies are not yet effectively implemented, controlling HCV transmission among IVDUs remains a challenge. The implementation of harm reduction policies, needle and syringe exchange programs, and the development of opioid substitution treatments have significantly contributed to reducing the prevalence of infectious diseases in industrialized countries. For instance, in France, the prevalence of HCV among IVDU aged 30 years or younger decreased from 44% in 2004 to 9% in 2011 (16). The study also shed light on the shifting patterns of transmission routes, with IVDU emerging as the most common transmission route. The substantial increase in the prevalence of IVDU as a transmission route, particularly in the later years studied, highlights the urgent need for inclusive harm reduction strategies, including needle exchange programs, opioid replacement therapy, and access to evidence-based addiction treatment services. Addressing the social determinants of health underlying substance use disorders is crucial for preventing new hepatitis C infections and reducing transmission rates within vulnerable populations.

The rise in the proportion of patients with a history of incarceration is another concerning trend identified in this study, particularly in the later years analyzed. All 9.1% of patients had a prison history; this rate was higher between 2018 and 2022 than the other year intervals (P < 0.001).

The higher prevalence of HCV among individuals with a history of incarceration underscores the importance of targeted screening and treatment

initiatives within correctional settings. Implementing comprehensive hepatitis C care programs in prisons can not only improve health outcomes for incarcerated individuals but also contribute to broader public health goals by reducing transmission rates in the community upon release. In Larney's study, the prevalence of anti-HCV in prisoners was reported to be 26%, while it could be up to 64% in IVDU prisoners. In the same study, while anti-HCV was 1.4% in the general population, anti-HCV was found to be 16.4% in IVDU individuals (17). In Çabalak's study, the prevalence of IVDU among prisoners with a high prevalence of HCV was 37.6%. They suggested that this might be due to the low number of patients and geographical region differences (16). In Zampino et al.'s study, the prevalence of anti-HCV in convicted patients was reported to range from 3% to 38% according to geographic region, IVDU, age, and prisoners' history (17). Preventing the spread of infectious diseases among prisoners by early diagnosis for the first time in a penal institution or already in a institution HBV, HCV, and penal human immunodeficiency virus (HIV) screening tests for all detainees. It is important to have it conducted voluntarily. This increase may be the result of increased screening of high-risk groups within the scope of hepatitis elimination programs in Turkey.

The analysis of disease characteristics, including HCV RNA levels, liver enzyme levels, and genotype distribution, provides valuable insights into the clinical profile of hepatitis C patients over time. The observed differences in HCV RNA levels and genotype distribution across the study periods may reflect changes in disease epidemiology, advancements in diagnostic technologies, or evolving treatment landscapes. The distribution of genotypes was found to be statistically different across time periods (P < 0.001). After 2013, almost half of the cases were infected with strains other than genotype 1. The increase in genotypes 2 and 3 was particularly notable. In 2014, a study conducted in the Çukurova region also found an increase in genotypes 2 and 3 and noted that the rate of IVDU in these cases was high (18).

Overall, the key findings reveal a gradual increase in diagnosed cases, a shift towards a younger age at diagnosis over time, and a notable rise in IVDU as a transmission route. All of these underscores the dynamic nature of hepatitis C epidemiology and highlight the importance of ongoing surveillance, prevention, and treatment efforts.

The study's limitations included its retrospective nature and single-center design, potentially limiting broader applicability. Selection bias towards more severe cases and variations in data completeness over time could affect the reliability of findings. In addition, the significant proportion of patients with unknown transmission routes and changes in diagnostic practices over the study period further complicate the interpretation of trends.

Footnotes

Authors' Contribution: Study concept and design, S. K.; acquisition of data, B. K., S. H. S.; analysis and interpretation of datam Y. K. A.; drafting of the manuscriptm S. K., B. K.; critical revision of the manuscript for important intellectual contentm S. K., A. C., F. K.; statistical analysis, Y. K. A.; administrative, technical, and material support, B. K., A. S. İ.; study supervision, Y. T.

Conflict of Interests Statement: All authors declare no conflict of interest. None of the authors are on the editorial board or serve as reviewers for this journal. None have personal financial interests.

Data Availability: The dataset presented in the study is available on request from the corresponding author during submission or after publication.

Ethical Approval: The study was conducted in accordance with the declaration of Helsinki, and the protocol was approved by the Ethics Committee of Cukurova University.

Funding/Support: This study had no funding or support.

References

- 1. World Health Organization. *Regional action plans for ending AIDS and the epidemics of viral hepatitis and sexually transmitted infections*. Geneva, Switzerland: World Health Organization; 2020. Available from: https://iris.who.int/handle/10665/361524.
- 2. World Health Organization. *Epidemiology of hepatitis C virus in the WHO eastern Mediterranean region: Implications for strategic action.* Geneva, Switzerland: World Health Organization; 2020. Available from: https://iris.who.int/handle/10665/336174.
- 3. World Health Organization. *Global hepatitis report 2017*. Geneva, Switzerland: World Health Organization; 2017. Available from: https://www.who.int/publications/i/item/9789241565455.
- Tozun N, Ozdogan O, Cakaloglu Y, Idilman R, Karasu Z, Akarca U, et al. Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study. *Clin Microbiol Infect.* 2015;**21**(11):1020-6. [PubMed ID: 26163105]. https://doi.org/10.1016/j.cmi.2015.06.028.

- Sibley A, Han KH, Abourached A, Lesmana LA, Makara M, Jafri W, et al. The present and future disease burden of hepatitis C virus infections with today's treatment paradigm - volume 3. J Viral Hepat. 2015;22 Suppl 4:21-41. [PubMed ID: 26513446]. https://doi.org/10.1111/jvh.12476.
- Irmak H, Yardım N, Keklik K, Temel F. Türkiye Viral Hepatit Önleme ve Kontrol Programı 2018-2023. 2019. Available from: https://hsgm.saglik.gov.tr/depo/Yayinlarimiz/Programlar/Turkiye_Vir al_Hepatit_Onleme_ve_Kontrol_Programi_2018-2023.pdf.
- Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. *J Hepatol*. 2014;61(1 Suppl):S45-57. [PubMed ID: 25086286]. https://doi.org/10.1016/j.jhep.2014.07.027.
- Ryerson AB, Schillie S, Barker LK, Kupronis BA, Wester C. Vital Signs: Newly Reported Acute and Chronic Hepatitis C Cases - United States, 2009-2018. MMWR Morb Mortal Wkly Rep. 2020;69(14):399-404. [PubMed ID: 32271725]. [PubMed Central ID: PMC7147907]. https://doi.org/10.15585/mmwr.mm6914a2.
- Schillie S, Wester C, Osborne M, Wesolowski L, Ryerson AB. CDC Recommendations for Hepatitis C Screening Among Adults - United States, 2020. *MMWR Recomm Rep.* 2020;69(2):1-17. [PubMed ID: 32271723]. [PubMed Central ID: PMC7147910]. https://doi.org/10.15585/mmwr.rr6902a1.
- Control ECfDPa. Introduction to the Annual Epidemiological Report. 2024. Available from: https://www.ecdc.europa.eu/en/surveillanceand-disease-data/annual-epidemiological-reports/introductionannual.
- Sarı ND, Baltalı S, Serin İ. Evaluation of Hepatitis C in 20 Years: A Turkish Experience. Bagcilar Medical Bulletin/Bağcılar Tıp Bülteni. 2023;8(4).
- Petruzziello A, Coppola N, Diodato AM, Iervolino V, Azzaro R, Di Costanzo G, et al. Age and gender distribution of hepatitis C virus genotypes in the metropolitan area of Naples. *Intervirol.* 2013;56(3):206-12. [PubMed ID: 23594735]. https://doi.org/10.1159/000348506.
- Alaei A, Alaei K, Waye K, Tracy M, Nalbandyan M, Mutlu E, et al. Hepatitis C infection and other drug-related harms among inpatients who injected drugs in Turkey. *J Viral Hepat.* 2017;**24**(6):496-505. [PubMed ID: 27925346]. https://doi.org/10.1111/jvh.12662.
- 14. Leon L, Kasereka S, Barin F, Larsen C, Weill-Barillet L, Pascal X, et al. Age- and time-dependent prevalence and incidence of hepatitis C virus infection in drug users in France, 2004-2011: model-based estimation from two national cross-sectional serosurveys. *Epidemiol Infect.* 2017;**145**(5):895-907. [PubMed ID: 28004616]. [PubMed Central ID: PMC9507806]. https://doi.org/10.1017/S0950268816002934.
- Larney S, Kopinski H, Beckwith CG, Zaller ND, Jarlais DD, Hagan H, et al. Incidence and prevalence of hepatitis C in prisons and other closed settings: results of a systematic review and meta-analysis. *Hepatol*. 2013;**58**(4):1215-24. [PubMed ID: 23504650]. [PubMed Central ID: PMC3723697]. https://doi.org/10.1002/hep.26387.
- Çabalak M, Bal T. Intravenous drug use rates and results of directacting antiviral treatment in prisoner patients. *Viral Hepatit Dergisis*. 2020;**26**(2):61.
- Zampino R, Coppola N, Sagnelli C, Di Caprio G, Sagnelli E. Hepatitis C virus infection and prisoners: Epidemiology, outcome and treatment. World J Hepatol. 2015;7(21):2323-30. [PubMed ID: 26413221]. [PubMed Central ID: PMC4577639]. https://doi.org/10.4254/wjh.v7.i21.2323.
- Kuşcu F, Kömür S, İnal AS, Ulu AC, Kurtaran B, Taşova Y, et al. Changing Epidemiology of Chronic Hepatitis C in Adana. Viral Hepatitis J/Viral Hepatit Dergisi. 2014;20(1).